Managing Director
New York Office | allen.lefkowitz@torreya.com | 212.257.5823
Allen Lefkowitz, Managing Director, leads Torreya’s Generic Pharmaceuticals Advisory team.
Allen has more than 20 years of business development, finance, and operating experience in life sciences. Having served in senior positions at the leading generics companies worldwide, he has worked on some of the largest transactions in the sector, including Sandoz’s landmark $1.5 billion acquisition of Fougera and Teva’s $3.4 billion acquisition of Sicor.
Before joining Torreya in 2013, Allen was Vice President of Business Development and Licensing at Sandoz USA, where he directed all generic and brand product licensing, as well as product and company acquisition activities. Previously, he spent nearly two decades at Teva in Israel and in the US, where he held positions in corporate and generics. He also served as global CFO of commercial operations for Teva API. He began his career at Schering-Plough.
Allen received his B.S. in economics and an M.B.A in finance/international business from New York University’s Stern School of Business. He is fluent in Hebrew.
![]() |
Sale of ANDA portfolio to |
![]() |
Undisclosed
January 2018
|
![]() |
Sale to |
![]() |
Undisclosed
January 2018
|
![]() |
Sale of company to |
![]() |
Undisclosed
June 2017
|
![]() |
Company sale to |
![]() |
$100+ million
December 2015
|
![]() |
Debt financing by |
![]() |
$57.5 million
February 2020
|
![]() |
BE Vaccines SAS sale to Clean Cells, a portfolio company of |
![]() |
Undisclosed
March 2019
|
![]() |
JV Partnership in China with |
![]() |
$50 million
December 2018
|
![]() |
Sale of Sevelamer ANDA to |
![]() |
Undisclosed
October 2018
|
![]() |
sale of Yargesa to |
![]() |
Undisclosed
June 2018
|
![]() |
Sale of OTC portfolio to |
![]() |
Undisclosed
December 2017
|
![]() |
Sale of majority equity stake to |
![]() |
Undisclosed
December 2017
|
![]() |
Sale of generics portfolio to |
![]() |
$18 million
August 2017
|
![]() |
Asset sale to |
![]() |
Undisclosed
July 2017
|
![]() |
Sale of selected generic brands to |
![]() |
Undisclosed
June 2017
|
![]() |
Sale of India women's health business to |
![]() |
Undisclosed
April 2017
|
![]() |
Sale of equity stake to |
![]() |
$33 million
November 2016
|
![]() |
Sale of ANDA portfolio to |
![]() |
Undisclosed
October 2016
|
![]() |
Sale of majority stake to |
![]() |
Undisclosed
July 2016
|
![]() |
Sale of abbreviated new drug applications |
![]() |
Undisclosed
February 2016
|
![]() |
Sale of assets to |
![]() |
$10 million
February 2016
|
![]() |
Senior term loan |
![]() |
$15 million
December 2015
|
![]() |
Acquisition of |
![]() |
CAD $47 million
October 2015
|
![]() |
Debt financing from |
![]() |
$20 million
September 2015
|
![]() |
Sale of abbreviated new drug application portfolio to |
![]() |
$25 million +
profit share July 2015
|
![]() |
Sale of Zonalon® to |
![]() |
Undisclosed
March 2015
|
![]() |
Divestiture of certain abbreviated new drug applications to |
![]() |
Up to $18 million
October 2014
|
![]() |
Sale of 31 abbreviated new drug applications to |
![]() |
$12.5 million +
profit share December 2013
|